Filing Flows › Alnylam Pharmaceuticals (ALNY) › R&D spending
Alnylam Pharmaceuticals (ALNY) R&D spending by quarter
Alnylam Pharmaceuticals' R&D spending was $409M in Q3 2026 (third quarter 2026), -1% from Q2 2026. Over the last 7 quarters it ranged from $265M (Q1 2025) to $413M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $409M | -1% | +14% |
| Q2 2026 | $413M | +11% | +28% |
| Q4 2025 | $372M | +4% | +24% |
| Q3 2025 | $359M | +11% | — |
| Q2 2025 | $324M | +22% | — |
| Q1 2025 | $265M | -12% | — |
| Q4 2024 | $300M | — | — |
Q3 2026 at a glance
Alnylam Pharmaceuticals, Q3 2026: revenue $1.5B (+17% year over year), operating margin 23.7%, net earnings $2.2B, operating cash flow $341M. The chart follows the revenue to costs, profit and cash.
Questions
What is Alnylam Pharmaceuticals' R&D spending?
Alnylam Pharmaceuticals' R&D spending was $409M in Q3 2026 (third quarter 2026), -1% from Q2 2026.
How has Alnylam Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $265M (Q1 2025) to $413M (Q2 2026).
Q3 2026 results → · How Alnylam Pharmaceuticals makes money →